Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Chuikyo Approves Outline for NHI Price Reform Including New Rule for Long-Listed Drugs; Trial of Premium for New Drug Development to Continue
December 26, 2013
-
REGULATORY FY2014 Budget: 95.4 Billion Yen for Japan NIH, Development of Novel Drugs
December 25, 2013
-
REGULATORY FY2014 NHI Price Revision Down 5.7% Excluding Tax Adjustments
December 24, 2013
-
BUSINESS Bristol to Sell Global Diabetes Biz to AstraZeneca; Deal Covers SGLT-2 Asset Transfer
December 20, 2013
-
REGULATORY Off-Patent Drugs to Get Continuous Price Cuts Until 60% Generic Share Reached
December 19, 2013
-
ACADEMIA Chiba University Finds No Proof of Manipulation in Diovan Study
December 18, 2013
-
BUSINESS Hyperlipidemia Treatment PCSK9 Inhibitors May Be Launched in Japan in 2016
December 17, 2013
-
REGULATORY Diovan Panel to Reopen Discussions on Dec. 25, Hear from 3 Universities
December 17, 2013
-
ACADEMIA Nagoya University Denies Diovan Clinical Data Manipulated
December 16, 2013
-
REGULATORY No Diovan, Livalo AGs for December Generic NHI Listing
December 13, 2013
-
BUSINESS AstraZeneca Japan Sees Annual Growth of Around 8%, Eyes Addition of 160 Reps
December 13, 2013
-
REGULATORY PFSB Begins Discussions Toward Lifting Ban on Subcontracting of Safety Management Tasks
December 12, 2013
-
BUSINESS Otsuka, Lundbeck to Codevelop Vaccine for Alzheimer’s Disease
December 12, 2013
-
ACADEMIA New Hepatitis C Guidelines Set Triple Therapy Including Simeprevir as 1st Choice
December 11, 2013
-
BUSINESS Takeda to Establish New CIO Post, Appoint Former Nestlé Exec
December 11, 2013
-
BUSINESS Drug Makers Invest in Developing AD Treatments
December 10, 2013
-
BUSINESS Ethical Drug Sales Up 2.5% in October: Crecon Report
December 10, 2013
-
REGULATORY FPMAJ OKs Concession Plan on Key Premium; Bill Payers Stick to Opposition
December 9, 2013
-
BUSINESS “Objective Accomplished,” Daiichi Sankyo to Terminate Ranmark Copromotion with AZ at Year-End
December 9, 2013
-
BUSINESS Generics Showed Strong Growth in 1st Half of FY2013 Despite Lack of New Measures to Promote Their Use
December 6, 2013
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…